Stem Cell Stocks Tick Higher After NIH Blood Stem-Cell Transplant Regimen Reverses Sickle Cell Disease in Adults

Late yesterday, NIH said a modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine.

The trial was conducted at the NIH Clinical Center in Bethesda, Md., by NIH researchers at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases.

Stem cell stocks could see reation to the news:

StemCells Inc. (Nasdaq: STEM)
Geron Corporation (Nasdaq: GERN)
Aastrom Biosciences, Inc. (Nasdaq: ASTM)

You May Also Be Interested In

• Wolfpack Research: 'we are short FTK because their $400m deal has been canceled'
• Avalonbay Communities (AVB) dropped from S&P 500
• Reddit (RDDT) added to S&P 500